NCT07439653
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Recruiting
PHASE1Ages 18+InterventionalTreatmentTORL Biotherapeutics, LLC
~155 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:TORL-5-700TORL-5-700 at MTD/RP2DTORL-5-700 at MTD/RP2D in combination with another agent
At a glance
Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluate the safety of TORL-5-700 as a monotherapy
Measured over though study completion, an average of 2.5 years
+4 more outcomes measured
Conditions
Where it's being run
3 sites across 2 statesCalifornia2
Tennessee1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
At least 1 measurable lesion per Lugano criteria.
Tumor tissue is available.
Adequate organ function
Exclusion
T-cell lymphoma
CLL or SL
Burkitt lymphoma and high-grade B-cell lymphoma
CNS involvement
Peripheral neuropathy \> Grade 2
Uncontrolled medical conditions
Viral infections
What this trial measures
- Evaluate the safety of TORL-5-700 as a monotherapythough study completion, an average of 2.5 years
Assessment of adverse events according to NCI-CTCAE Version 5.0
- Assess the antitumor activity of TORL-5-700 as monotherapythough study completion, an average of 2.5 years
Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria
- Evaluate the safety of TORL-5-700 in combination with other agentsthough study completion, an average of 2.5 years
Assessment of adverse events according to NCI-CTCAE Version 5.0
- Determine the Maximum Tolerated Dose (MTD)21 days from the start of treatment
Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)
- Determine the Recommended Phase 2 Dose (RP2D)21 days from the start of treatment
Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities